Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 127Active not recruiting 13Recruiting 10Terminated 8Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 14NETWORK 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Radiotherapy 5Biopsy 4Radiation 3High-Energy Shock Waves 3Cyclophosphamide 3venetoclax 2X-Rays 2Vincristine 2Spinal Puncture 2Sentinel Lymph Node Biopsy 2Radiosurgery 2Paclitaxel 2Daunorubicin 2Cytarabine 2Azacitidine 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1taxane 1sulforaphane 1sacituzumab govitecan 1revumenib 1prednylidene 1pertuzumab 1pembrolizumab 1pegaspargase 1nelarabine 1merphos 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × NETWORK × Vincristine × Clear all
NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡